|
1
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sudo K, Nakamura K and Yamaguchi T: S-1 in
the treatment of pancreatic cancer. World J Gastroenterol.
20:15110–15118. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cid-Arregui A and Juarez V: Perspectives
in the treatment of pancreatic adenocarcinoma. World J
Gastroenterol. 21:9297–9316. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Malvezzi M, Bertuccio P, Levi F, La
Vecchia C and Negri E: European cancer mortality predictions for
the year 2013. Ann Oncol. 24:792–800. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Imaoka H, Kou T, Tanaka M, Egawa S, Mizuno
N, Hijioka S, Hara K, Yazumi S, Shimizu Y and Yamao K: Clinical
outcome of elderly patients with unresectable pancreatic cancer
treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone:
Subgroup analysis of a randomised phase III trial, GEST study. Eur
J Cancer. 54:96–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaga Y, Sunakawa Y, Kubota Y, Tagawa T,
Yamamoto T, Ikusue T, Uto Y, Miyashita K, Toshima H, Kobayashi K,
et al: Early tumor shrinkage as a predictor of favorable outcomes
in patients with advanced pancreatic cancer treated with
FOLFIRINOX. Oncotarget. 7:67314–67320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boursi B, Finkelman B, Giantonio BJ,
Haynes K, Rustgi AK, Rhim AD, Mamtani R and Yang YX: A clinical
prediction model to assess risk for pancreatic cancer among
patients with new-onset diabetes. Gastroenterology. 152:840–850.e3.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
American Cancer Society, . Cancer Facts
& Figures 2013. American Cancer Society, Inc.; Atlanta, GA:
2013
|
|
11
|
Muller MJ, Wang Z, Heymsfield SB, Schautz
B and Bosy-Westphal A: Advances in the understanding of specific
metabolic rates of major organs and tissues in humans. Curr Opin
Clin Nutr Metab Care. 16:501–508. 2013.PubMed/NCBI
|
|
12
|
Dasarathy S: Consilience in sarcopenia of
cirrhosis. J Cachexia Sarcopenia Muscle. 3:225–237. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rosenberg IH: Sarcopenia: Origins and
clinical relevance. J Nutr. 127 5 Suppl:990S–991S. 1997.PubMed/NCBI
|
|
14
|
Wang C and Bai L: Sarcopenia in the
elderly: Basic and clinical issues. Geriatr Gerontol Int.
12:388–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fukushima H, Nakanishi Y, Kataoka M,
Tobisu K and Koga F: Prognostic significance of sarcopenia in
patients with metastatic renal cell carcinoma. J Urol. 195:26–32.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Levolger S, van Vugt JL, de Bruin RW and
IJzermans JN: Systematic review of sarcopenia in patients operated
on for gastrointestinal and hepatopancreatobiliary malignancies. Br
J Surg. 102:1448–1458. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Prado CM, Lieffers JR, McCargar LJ, Reiman
T, Sawyer MB, Martin L and Baracos VE: Prevalence and clinical
implications of sarcopenic obesity in patients with solid tumors of
the respiratory and gastrointestinal tracts: A population based
study. Lancet Oncol. 9:629–635. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chindapasirt J: Sarcopenia in Cancer
Patients. Asian Pac J Cancer Prev. 16:8075–8077. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Dijk DP, Bakens MJ, Coolsen MM, Rensen
SS, van Dam RM, Bours MJ, Weijenberg MP, Dejong CH and Damink SW
Olde: Low skeletal muscle radiation attenuation and visceral
adiposity are associated with overall survival and surgical site
infections in patients with pancreatic cancer. J Cachexia
Sarcopenia Muscle. 8:317–326. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Carrara G, Pecorelli N, De Cobelli F,
Cristel G, Damascelli A, Beretta L and Braga M: Preoperative
sarcopenia determinants in pancreatic cancer patients. Clin Nutr.
Oct 20–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Onesti JK, Wright GP, Kenning SE, Tierney
MT, Davis AT, Doherty MG and Chung MH: Sarcopenia and survival in
patients undergoing pancreatic resection. Pancreatology.
16:284–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Amini N, Spolverato G, Gupta R, Margonis
GA, Kim Y, Wagner D, Rezaee N, Weiss MJ, Wolfgang CL, Makary MM, et
al: Impact total psoas volume on short- and long-term outcomes in
patients undergoing curative resection for pancreatic
adenocarcinoma: N new tool to assess sarcopenia. J Gastrointest
Surg. 19:1593–1602. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zalite I Ozola, Zykus R, Gonzalez M
Francisco, Saygili F, Pukitis A, Gaujoux S, Charnley RM and Lyadov
V: Influence of cachexia and sarcopenia on survival in pancreatic
ductal adenocarcinoma: A systematic review. Pancreatology.
15:19–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Choi Y, Oh DY, Kim TY, Lee KH, Han SW, Im
SA, Kim TY and Bang YJ: Skeletal muscle depletion predicts the
prognosis of patients with advanced pancreatic cancer undergoing
palliative chemotherapy, independent of body mass index. PLoS One.
10:e01397492015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park I, Choi SJ, Kim YS, Ahn HK, Hong J,
Sym SJ, Park J, Cho EK, Lee JH, Shin YJ and Shin DB: Prognostic
factors for risk stratification of patients with recurrent or
metastatic pancreatic adenocarcinoma who were treated with
gemcitabine-based chemotherapy. Cancer Res Treat. 48:1264–1273.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nawaz H, Fan CY, Kloke J, Khalid A,
McGrath K, Landsittel D and Papachristou GI: Performance
characteristics of endoscopic ultrasound in the staging of
pancreatic cancer: A meta-analysis. JOP. 14:484–497.
2013.PubMed/NCBI
|
|
29
|
Zhao WY, Luo M, Sun YW, Xu Q, Chen W, Zhao
G and Wu ZY: Computed tomography in diagnosing vascular invasion in
pancreatic and periampullary cancers: A systematic review and
meta-analysis. Hepatobiliary Pancreat Dis Int. 8:457–464.
2009.PubMed/NCBI
|
|
30
|
Yang R, Lu M, Qian X, Chen J, Li L, Wang J
and Zhang Y: Diagnostic accuracy of EUS and CT of vascular invasion
in pancreatic cancer: A systematic review. J Cancer Res Clin Oncol.
140:2077–2086. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Puli SR, Singh S, Hagedorn CH, Reddy J and
Olyaee M: Diagnostic accuracy of EUS for vascular invasion in
pancreatic and periampullary cancers: A meta-analysis and
systematic review. Gastrointest Endosc. 65:788–797. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Doi R, Imamura M, Hosotani R, Imaizumi T,
Hatori T, Takasaki K, Funakoshi A, Wakasugi H, Asano T, Hishinuma
S, et al: Surgery versus radiochemotherapy for resectable locally
invasive pancreatic cancer: Final results of a randomized
multi-institutional trial. Surg Today. 38:1021–1028. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Okumura S, Kaido T, Hamaguchi Y, Fujimoto
Y, Masui T, Mizumoto M, Hammad A, Mori A, Takaori K and Uemoto S:
Impact of preoperative quality as well as quantity of skeletal
muscle on survival after resection of pancreatic cancer. Surgery.
157:1088–1098. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hamaguchi Y, Kaido T, Okumura S, Kobayashi
A, Hammad A, Tamai Y, Inagaki N and Uemoto S: Proposal for new
diagnostic criteria for low skeletal muscle mass based on computed
tomography imaging in Asian adults. Nutrition. 32:1200–1205. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamaguchi K, Okusaka T, Shimizu K, Furuse
J, Ito Y, Hanada K and Shimosegawa T; Committee for revision of
clinical guidelines for pancreatic cancer of Japan Pancreas
Society, : EBM-based clinical guidelines for pancreatic cancer
(2013) issued by the japan pancreas society: A synopsis. Jpn J Clin
Oncol. 44:883–888. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hewitt MJ, McPhail MJ, Possamai L, Dhar A,
Vlavianos P and Monahan KJ: EUS-guided FNA for diagnosis of solid
pancreatic neoplasms: A meta-analysis. Gastrointest Endosc.
75:319–331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ishii H, Furuse J, Boku N, Okusaka T,
Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K and Fukuda H;
JCOG Gastrointestinal Oncology Study Group, : Phase II study of
gemcitabine chemotherapy alone for locally advanced pancreatic
carcinoma: JCOG0506. Jpn J Clin Oncol. 40:573–579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Le N, Sund M and Vinci A; GEMS
collaborating group of Pancreas, : 2000 Prognostic and predictive
markers in pancreatic adenocarcinoma. Dig Liver Dis. 48:223–230.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mahmoud FA and Rivera NI: The role of
C-reactive protein as a prognostic indicator in advanced cancer.
Curr Oncol Rep. 4:250–255. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Speck RM, Courneya KS, Mâsse LC, Duval S
and Schmitz KH: An update of controlled physical activity trials in
cancer survivors: A systematic review and meta-analysis. J Cancer
Surviv. 4:87–100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Neuzillet C, Vergnault M, Bonnetain F and
Hammel P: Rationale and design of the Adapted Physical Activity in
advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe
Coopérateur Multidisciplinaire en Oncologie) trial: Study protocol
for a randomized controlled trial. Trials. 16:4542015. View Article : Google Scholar : PubMed/NCBI
|
